Citeline, Biomedtracker: 開発中医薬品をFDA承認確率で評価, Pharma consultin...
Catch up on any missed COVID-19 24 hour webinar sessions
The 34th annual JP Morgan Healthcare Conference is being held in San Francisco, CA from January 11- 14, 2016. A list of events and catalysts that were announced or updated at the conference today is included in this report. Additionally, below are some key points from today’s company presentations. Drug pricing has received a lot of negative press, so at the opening luncheon, it was interesting to hear JPM Chairman and CEO, Jaime Dimon suggest that nothing would really change with a new administration. He did add, however, that a new administration could address tax policy that would affect acquisitions that effectively move companies overseas like the recent Pfizer-Allergan deal.
Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biomedtracker: 開発中医...
By Dustin Phan
The effect of COVID-19 on clinical trials, the industry response, and the return to full operations
Pharmaprojects: 医薬品開発パイプラインのデータベース, Biomedtracker: 開発中医薬品をFD...
Access this infographic which focuses on Gilead’s drug Remdesivir which currently shows the greatest promise for the likelihood of approval as a possible treatment to effectively treat the virus. The infographic highlights the drug summary and profile, the number of patients in each trial phase, and the history of events that have moved this product through the development process.